The MarginProbe System provides real time, intraoperative detection of cancerous tissue at the edges of excised breast tissue.
Officials at Dune Medical Devices Inc. announce that the company has received an Approvable Letter for its Premarket Approval Application (PMA) from the Food and Drug Administration. The Approvable Letter states that the MarginProbe System PMA is approvable subject to final agreement with FDA on the design of the required Post Approval Study.
"We are delighted to have come to this point in the approval process with FDA and will work diligently over the coming weeks to develop the final design of the Post Approval Study. Having completed our discussions with FDA related to product labeling, the Post Approval Study is the only remaining issue to be resolved prior to final approval," says Daniel Levangie, CEO of Dune Medical Devices.
About Early-Stage Breast Cancer Treatment
Breast cancer is the most common type of cancer affecting women in the U.S., with more than 285,000 women diagnosed each year. Increased breast screening awareness and advancements in imaging technology such as mammograms now catch more breast cancer cases in earlier stages, when they are most treatable. In fact, more than half of all breast cancer diagnoses are for early-stage cancers. Many of these cases are non-palpable, meaning a tumor cannot be felt during a breast exam.
It is estimated that 60% to 75% of breast cancer cases will undergo a lumpectomy procedure as their initial treatment versus mastectomy, which involves the removal of the whole breast. Lumpectomy in combination with radiation therapy is as effective in combating breast cancer as mastectomy, as long as no cancer cells are present on the rim or edge of the removed tissue, also known as "clean margins." Research shows there is no significant difference in overall survival between the two procedures; however, if there is cancer at the edge, or a "positive margin," the risk of recurrence increases significantly.
Following a lumpectomy, surgeons will send the removed tissue to the pathology lab where it is analyzed for cancer on the margin. This is critical information because if there is cancer present on the edges of the removed tissue, there is a possibility that cancer still remains in the breast. Once a tissue sample is sent to pathology for analysis, it can take approximately one week or more to receive the lab results that determine if the patient must undergo a repeat surgery.
Inability to know if all cancerous cells have been removed from the breast during the initial lumpectomy procedure results in repeat surgery rates ranging from 30% to 60%.